Literature DB >> 19007330

Translating molecular insights in autoimmunity into effective therapy.

Marc Feldmann1.   

Abstract

Autoimmunity and the pathogenesis of autoimmune diseases were a major focus of the Walter and Eliza Hall Institute, where I started my research career. After my initial studies on immune cell culture and immune regulation, I returned to an analysis of the pathogenesis of human autoimmunity in London. Linking upregulated antigen presentation to autoimmunity led to an investigation of the role of cytokines in rheumatoid arthritis (RA), in collaboration with Ravinder Maini. These experiments defined the concept of a TNF-dependent cytokine cascade driving the manifestations of RA, which led to successful clinical trials of anti-TNF monoclonal antibody in RA patients, heralding a major change in medical practice. This success was made possible by enthusiastic support from many laboratory and clinical colleagues and taught us that cytokines are important rate-limiting steps and hence good therapeutic targets. My current scientific challenge is exploring the hypothesis of whether all major medical needs can be approached via cytokine blockade.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19007330     DOI: 10.1146/annurev-immunol-082708-100732

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  22 in total

1.  HBEGF+ macrophages in rheumatoid arthritis induce fibroblast invasiveness.

Authors:  David Kuo; Jennifer Ding; Ian S Cohn; Fan Zhang; Kevin Wei; Deepak A Rao; Cristina Rozo; Upneet K Sokhi; Sara Shanaj; David J Oliver; Adriana P Echeverria; Edward F DiCarlo; Michael B Brenner; Vivian P Bykerk; Susan M Goodman; Soumya Raychaudhuri; Gunnar Rätsch; Lionel B Ivashkiv; Laura T Donlin
Journal:  Sci Transl Med       Date:  2019-05-08       Impact factor: 17.956

2.  The interferon signature and STAT1 expression in rheumatoid arthritis synovial fluid macrophages are induced by tumor necrosis factor α and counter-regulated by the synovial fluid microenvironment.

Authors:  Rachael A Gordon; Galina Grigoriev; Angela Lee; George D Kalliolias; Lionel B Ivashkiv
Journal:  Arthritis Rheum       Date:  2012-10

Review 3.  TNF biology, pathogenic mechanisms and emerging therapeutic strategies.

Authors:  George D Kalliolias; Lionel B Ivashkiv
Journal:  Nat Rev Rheumatol       Date:  2015-12-10       Impact factor: 20.543

4.  Tumor necrosis factor α induces sustained signaling and a prolonged and unremitting inflammatory response in rheumatoid arthritis synovial fibroblasts.

Authors:  Angela Lee; Yu Qiao; Galina Grigoriev; Janice Chen; Kyung-Hyun Park-Min; Sung Ho Park; Lionel B Ivashkiv; George D Kalliolias
Journal:  Arthritis Rheum       Date:  2013-04

Review 5.  Targeting Toll-like receptors: emerging therapeutics?

Authors:  Elizabeth J Hennessy; Andrew E Parker; Luke A J O'Neill
Journal:  Nat Rev Drug Discov       Date:  2010-04       Impact factor: 84.694

Review 6.  Selected cytokine pathways in rheumatoid arthritis.

Authors:  Mélissa Noack; Pierre Miossec
Journal:  Semin Immunopathol       Date:  2017-02-17       Impact factor: 9.623

7.  Modulation of TNF-induced macrophage polarization by synovial fibroblasts.

Authors:  Laura T Donlin; Arundathi Jayatilleke; Eugenia G Giannopoulou; George D Kalliolias; Lionel B Ivashkiv
Journal:  J Immunol       Date:  2014-07-23       Impact factor: 5.422

Review 8.  Insights into the biology and therapeutic implications of TNF and regulatory T cells.

Authors:  Benoit L Salomon
Journal:  Nat Rev Rheumatol       Date:  2021-07-05       Impact factor: 20.543

9.  Phellinus baumii ethyl acetate extract alleviated collagen type II induced arthritis in DBA/1 mice.

Authors:  Taddesse Yayeh; Whi Min Lee; Dukhwan Ko; Seung-Choon Park; Jae Youl Cho; Hwa-Jin Park; In-Kyoung Lee; Seung-Hyung Kim; Seung-Bok Hong; Suk Kim; Bong-Sik Yun; Man Hee Rhee
Journal:  J Nat Med       Date:  2013-03-06       Impact factor: 2.343

Review 10.  Proinflammatory Cytokines Mediate GPCR Dysfunction.

Authors:  Maradumane L Mohan; Neelakantan T Vasudevan; Sathyamangla V Naga Prasad
Journal:  J Cardiovasc Pharmacol       Date:  2017-08       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.